Gene therapy involves introducing exogenous genes into target cells to replace or correct the expression of defective and abnormal genes, thereby changing the biological characteristics of the cells and achieving the purpose of treating diseases. With the rapid development of gene-related technologies, the application value of gene drugs in the fields of genetic and non-genetic diseases has rapidly become prominent and has continued to attract capital markets. As of December 8, 2023, six gene therapy products have been approved for market launch, marking a rapid development stage for gene therapy.
Frost & Sullivan hereby releases the 'Blue Book on the Current Status and Development Trends of the Gene Drug Industry', aiming to conduct an in-depth analysis of the gene drug field. It provides a comprehensive exposition from multiple dimensions such as technological development, application areas, marketed products, R&D status, patient needs, capital enthusiasm, industry structure, etc., tracks the context of industry and technological development, explores the huge potential for industry development, and analyzes the driving factors behind market development.
